Roidipedia.Compound reference & reporting
05 AUG 2026
CompoundsPharmaceutical Naltrexone/Bupropion (Contrave)
PharmaceuticalDNRIAnti-obesity combinationOpioid antagonist

Naltrexone/Bupropion (Contrave)

Also known as Contrave · Mysimba · NB-32

A fixed-dose combination of the opioid antagonist naltrexone and the dopamine-noradrenaline reuptake inhibitor bupropion, approved as Contrave (Mysimba in Europe) in 2014 for weight management. It targets appetite and reward pathways, giving modest weight loss with characteristic nausea and a boxed warning around bupropion's psychiatric effects.

01 Overview

Contrave combines sustained-release naltrexone and bupropion. Bupropion stimulates hypothalamic POMC neurons to reduce appetite; naltrexone blocks an opioid-mediated feedback loop that otherwise limits that effect, and the pair also dampens food-reward drive. Trials (COR programme) showed roughly 4-5% placebo-subtracted weight loss.

It is neither the strongest nor the weakest oral option. Nausea is very common, and because bupropion is an antidepressant it carries the class boxed warning for suicidality in younger patients and a seizure risk. It is contraindicated with opioids and in uncontrolled hypertension.

02 Mechanism

Bupropion activates POMC neurons (via dopamine/noradrenaline reuptake inhibition) to suppress appetite; naltrexone blocks beta-endorphin autoinhibition of those neurons, and both reduce reward-driven eating.

03 Dosing

TierDoseRouteNotes
Titration8–90 mg/dayOralStart one tablet (8 mg naltrexone / 90 mg bupropion) daily, escalating weekly.
Maintenance dose32–360 mg/dayOralTwo tablets twice daily (32 mg naltrexone / 360 mg bupropion total).

04 Effects

EffectMagnitudeEvidence
Weight lossModest weight reduction with reduced appetite and food craving.~4-5% vs placeboClinical
Reduced food reward/cravingDampened hedonic drive to eat, useful for craving-driven overeating.moderateClinical

05 Side effects

EffectSeverityFrequencyEvidenceCountermeasures
Nausea and vomitingNausea, constipation and vomiting, the leading cause of discontinuation.ModerateVery commonClinical
Psychiatric effects and seizure riskBupropion carries a suicidality boxed warning and lowers seizure threshold.SevereRare (boxed warning)Clinical
Blood pressure and heart rate increaseSmall increases in BP and pulse.ModerateCommonClinical

07 References

Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I)The Lancet, 2010 (Greenway et al.)

08 Discussion0 comments

?
Sign in to add a comment…
Create account
Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.
This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.